Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hyeong-Seok Joo"'
Autor:
Seok-Young Kim, Ji Yeon Lee, Dong Hwi Kim, Hyeong -Seok Joo, Mi Ran Yun, Dongmin Jung, Jiyeon Yun, Seong Gu Heo, Beung -Chul Ahn, Chae Won Park, Kyoung Ho Pyo, You Jin Chun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Adequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies
Externí odkaz:
https://doaj.org/article/a381d185621a4cc6965c977aa42e9fc1
Autor:
Mi Ran Yun, Hun Mi Choi, You Won Lee, Hyeong Seok Joo, Chae Won Park, Jae Woo Choi, Dong Hwi Kim, Han Na Kang, Kyoung‐Ho Pyo, Eun Joo Shin, Hyo Sup Shim, Ross A Soo, James Chih‐Hsin Yang, Sung Sook Lee, Hyun Chang, Min Hwan Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 12, Pp n/a-n/a (2019)
Abstract Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We
Externí odkaz:
https://doaj.org/article/d4178ca591ff41c1b89ca89a0354a643
Autor:
Byoung Chul Cho, Hye Ryun Kim, J. Jean Cui, Min Hee Hong, Hyo Sup Shim, Seok-Gu Kang, Alexander Drilon, Adam J. Schoenfeld, Sung Sook Lee, Han Na Kang, Seong Gu Heo, Chae Won Park, Hun Mi Choi, You Won Lee, Hyeong-Seok Joo, Seok-Young Kim, Dong Hwi Kim, Mi Ran Yun
Purpose:Although first-line crizotinib treatment leads to clinical benefit in ROS1+ lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1G2032R) mutation and progression in the central nervous system (CNS) represents a therapeutic ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb04a28e7405b3dbb222e697738e45e
https://doi.org/10.1158/1078-0432.c.6529067
https://doi.org/10.1158/1078-0432.c.6529067
Autor:
Byoung Chul Cho, Hye Ryun Kim, J. Jean Cui, Min Hee Hong, Hyo Sup Shim, Seok-Gu Kang, Alexander Drilon, Adam J. Schoenfeld, Sung Sook Lee, Han Na Kang, Seong Gu Heo, Chae Won Park, Hun Mi Choi, You Won Lee, Hyeong-Seok Joo, Seok-Young Kim, Dong Hwi Kim, Mi Ran Yun
Supplementary table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be66098c51dae65b0cf889710dac01f
https://doi.org/10.1158/1078-0432.22475384.v1
https://doi.org/10.1158/1078-0432.22475384.v1
Autor:
Hye Ryun Kim, Seong Gu Heo, Sung Sook Lee, Seok Young Kim, Min Hee Hong, Mi Ran Yun, Hyo Sup Shim, Han Na Kang, J. Jean Cui, Chae Won Park, Alexander Drilon, Hyeong Seok Joo, Dong Hwi Kim, Adam J. Schoenfeld, You Won Lee, Seok Gu Kang, Byoung Chul Cho, Hun Mi Choi
Publikováno v:
Clin Cancer Res
Purpose: Although first-line crizotinib treatment leads to clinical benefit in ROS1+ lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1G2032R) mutation and progression in the central nervous system (CNS) represents a therapeutic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b4fef3514dfb3a6b8c6fcc443792c5
https://europepmc.org/articles/PMC10283448/
https://europepmc.org/articles/PMC10283448/
Autor:
Jeong-Yeon Lee, Taekwon Son, Hyeong Seok Joo, Hee Woon An, Sora Jin, Kyueng-Whan Min, Young Ha Oh, Hee Joo Choi, Gu Kong, Hyung-Yong Kim, Wan Seop Kim, Ga Young Jeong, Seung Eun Lee, Mi Kyung Park
Publikováno v:
JNCI: Journal of the National Cancer Institute. 111:609-619
Resistance to HER2-targeted therapy with trastuzumab still remains a major challenge in HER2-amplified tumors. Here we investigated the potential role of MEL-18, a polycomb group gene, as a novel prognostic marker for trastuzumab resistance in HER2-p
Autor:
Hyo Sup Shim, Han Na Kang, Min Hwan Kim, Hye Ryun Kim, Hyeong Seok Joo, You Won Lee, James Chih-Hsin Yang, Ross A. Soo, Min Hee Hong, Mi Ran Yun, Dong Hwi Kim, Sung Sook Lee, Hun Mi Choi, Jae Woo Choi, Chae Won Park, Eun joo Shin, Kyoung Ho Pyo, Byoung Chul Cho, Hyun Chang
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 12, Pp n/a-n/a (2019)
EMBO Molecular Medicine
EMBO Molecular Medicine
Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We investiga
Autor:
Kyueng-Whan Min, Hyeong-Seok Joo, Hee-Young Won, Hee Joo Choi, Taekwon Son, Hyung-Yong Kim, Young Ha Oh, Jeong-Yeon Lee, Gu Kong
Publikováno v:
JNCI: Journal of the National Cancer Institute. 110:400-410
Background Despite the benefit of endocrine therapy, acquired resistance during or after treatment still remains a major challenge in estrogen receptor (ER)-positive breast cancer. We investigated the potential role of histone demethylase retinoblast
Autor:
Kyoung Ho Pyo, Byoung Chul Cho, Hyeong Seok Joo, Jiyeon Yun, Min Hee Hong, Mi Ran Yun, Chae Won Park, Seong Gu Heo, Seok Young Kim, Hye Ryun Kim, Dongmin Jung, You Jin Chun, Beung Chul Ahn, Ji-Yeon Lee, Dong Hwi Kim
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Adequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies and nove
Publikováno v:
Maintenance, Safety, Risk, Management and Life-Cycle Performance of Bridges ISBN: 9781315189390
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::398ea480ffa6ff7cd487849343580347
https://doi.org/10.1201/9781315189390-367
https://doi.org/10.1201/9781315189390-367